Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
08 2019
Historique:
received: 16 01 2019
accepted: 15 04 2019
revised: 21 03 2019
pubmed: 1 5 2019
medline: 18 3 2020
entrez: 1 5 2019
Statut: ppublish

Résumé

Standard depression treatments, including antidepressant medication and cognitive behavioural therapy (CBT), are ineffective for many patients. Prefrontal transcranial direct current stimulation (tDCS) has been proposed as an alternative treatment, but has shown inconsistent efficacy for depression, and its mechanisms are poorly understood. We recruited unmedicated patients with major depressive disorder (N = 71 approached; N = 39 randomised) for a mechanistic, double-blind, randomized controlled trial consisting of eight weekly sessions of prefrontal tDCS administered to the left prefrontal cortex prior to CBT. We probed (1) whether tDCS improved the efficacy of CBT relative to sham stimulation; and (2) whether neural measures predicted clinical response. We found a modest and non-significant effect of tDCS on clinical outcome over and above CBT (active: 50%; sham: 31.6%; odds ratio: 2.16, 95% CI = 0.59-7.99), but a strong relationship, predicted a priori, between baseline activation during a working memory task in the stimulated prefrontal region and symptom improvement. Repeating our analyses of symptom outcome splitting the sample according to this biomarker revealed that tDCS was significantly superior to sham in individuals with high left prefrontal cortex activation at baseline; we also show 86% accuracy in predicting clinical response using this measure. Exploratory analyses revealed several other regions where activation at baseline was associated with subsequent response to CBT, irrespective of tDCS. This mechanistic trial revealed variable, but predictable, clinical effects of prefrontal tDCS combined with CBT for depression. We have discovered a potential explanation for this variability: individual differences in baseline activation of the region stimulated. Such a biomarker could potentially be used to pre-select patients for trials and, eventually, in the clinic.

Identifiants

pubmed: 31039579
doi: 10.1038/s41386-019-0401-0
pii: 10.1038/s41386-019-0401-0
pmc: PMC6784995
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1613-1622

Subventions

Organisme : Medical Research Council
ID : MC_U105579215
Pays : United Kingdom
Organisme : Brain and Behavior Research Foundation (Brain & Behavior Research Foundation)
ID : 20162
Pays : International

Références

Front Syst Neurosci. 2013 Nov 28;7:99
pubmed: 24348348
Int J Neuropsychopharmacol. 2014 Sep;17(9):1443-52
pubmed: 24713139
Bipolar Disord. 2006 Apr;8(2):203-4
pubmed: 16542193
Brain Stimul. 2015 May-Jun;8(3):663-5
pubmed: 25921355
J Neurosci. 2013 Jul 10;33(28):11425-31
pubmed: 23843514
Int J Neuropsychopharmacol. 2008 Mar;11(2):249-54
pubmed: 17559710
Brain Stimul. 2014 Mar-Apr;7(2):325-31
pubmed: 24486425
Am J Psychiatry. 2006 Apr;163(4):735-8
pubmed: 16585452
Brain Stimul. 2012 Apr;5(2):110-5
pubmed: 22483547
Br J Psychiatry. 2012 Jan;200(1):52-9
pubmed: 22215866
F1000Res. 2013 Oct 17;2:219
pubmed: 24555105
Exp Brain Res. 2005 Sep;166(1):23-30
pubmed: 15999258
Neuroimage. 2016 Aug 15;137:140-151
pubmed: 27188218
Neurology. 2001 Nov 27;57(10):1899-901
pubmed: 11723286
Neurosci Lett. 2013 Mar 14;537:60-4
pubmed: 23370288
Brain Stimul. 2014 Nov-Dec;7(6):773-83
pubmed: 25456566
Neuropsychologia. 2019 May;128:332-339
pubmed: 29630916
Brain Stimul. 2015 May-Jun;8(3):535-50
pubmed: 25701175
Brain Stimul. 2018 Jan - Feb;11(1):125-133
pubmed: 29111077
J Affect Disord. 2013 Sep 5;150(2):699-702
pubmed: 23707032
Neuroimage. 2017 Aug 1;156:119-127
pubmed: 28506872
Brain Stimul. 2013 May;6(3):465-7
pubmed: 23031723
Arch Gen Psychiatry. 2005 Apr;62(4):409-16
pubmed: 15809408
J Affect Disord. 2011 Nov;134(1-3):459-63
pubmed: 21641047
Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45
pubmed: 21320389
Biol Psychiatry. 2005 Apr 1;57(7):809-12
pubmed: 15820239
Annu Rev Psychol. 2006;57:285-315
pubmed: 16318597
Psychol Med. 2012 Jan;42(1):29-40
pubmed: 21733287
Biol Psychiatry. 2007 Jan 15;61(2):198-209
pubmed: 17027931
Brain Stimul. 2012 Oct;5(4):499-504
pubmed: 22405745
J Neurosci. 2009 Jun 3;29(22):7271-7
pubmed: 19494149
Soc Cogn Affect Neurosci. 2017 May 1;12(5):839-847
pubmed: 28158703
N Engl J Med. 2017 Jun 29;376(26):2523-2533
pubmed: 28657871
Am J Psychiatry. 2007 Aug;164(8):1242-9
pubmed: 17671288
Neuromodulation. 2019 Dec;22(8):898-903
pubmed: 30153360
Brain Stimul. 2010 Oct;3(4):207-10
pubmed: 20965449
JAMA Psychiatry. 2013 Apr;70(4):383-91
pubmed: 23389323
Neuropsychopharmacology. 2012 Jan;37(1):117-36
pubmed: 21976044
Dialogues Clin Neurosci. 2014 Dec;16(4):479-90
pubmed: 25733953
Hum Brain Mapp. 2005 May;25(1):46-59
pubmed: 15846822
J Cogn Neurosci. 2011 Nov;23(11):3681-93
pubmed: 21568644
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:101-8
pubmed: 25174680

Auteurs

Camilla L Nord (CL)

Institute of Cognitive Neuroscience, University College London, London, UK. Camilla.Nord@mrc-cbu.cam.ac.uk.
MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK. Camilla.Nord@mrc-cbu.cam.ac.uk.

D Chamith Halahakoon (DC)

Institute of Cognitive Neuroscience, University College London, London, UK.
Department of Psychiatry, University of Oxford, Oxford, UK.

Tarun Limbachya (T)

Camden and Islington NHS Foundation Trust, London, UK.

Caroline Charpentier (C)

Institute of Cognitive Neuroscience, University College London, London, UK.
Division of the Humanities and Social Sciences, California Institute of Technology, California, USA.

Níall Lally (N)

Institute of Cognitive Neuroscience, University College London, London, UK.
Warwick Medical School, University of Warwick, Coventry, UK.
Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Vincent Walsh (V)

Institute of Cognitive Neuroscience, University College London, London, UK.

Judy Leibowitz (J)

Camden and Islington NHS Foundation Trust, London, UK.

Stephen Pilling (S)

Camden and Islington NHS Foundation Trust, London, UK.
Department of Clinical, Educational, and Health Psychology, University College London, London, UK.

Jonathan P Roiser (JP)

Institute of Cognitive Neuroscience, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH